NCT06601985

Brief Summary

The occurrence of colorectal cancer has increased from the third most common cancer in 2018 to the second most common cancer in 2023. The practice of anal preservation surgery for ultra-low rectal cancer is being adopted gradually. Ultra-low rectal cancer patients who have undergone anal preservation are at an increased risk of developing significant bowel complications. The objective of this study was to examine the relationship between the type of bowel reconstruction following anal preservation surgery, and the subsequent outcomes of bowel function, quality of life and complication rates in patients with ultra-low rectal cancer.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
154

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Dec 2022

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 1, 2022

Completed
1.8 years until next milestone

First Submitted

Initial submission to the registry

September 15, 2024

Completed
4 days until next milestone

First Posted

Study publicly available on registry

September 19, 2024

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 11, 2025

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

April 11, 2025

Completed
Last Updated

September 19, 2024

Status Verified

September 1, 2024

Enrollment Period

2.3 years

First QC Date

September 15, 2024

Last Update Submit

September 17, 2024

Conditions

Outcome Measures

Primary Outcomes (4)

  • LARS score

    The LARS scale has five questions with a total score of 42. A score of 0-20 lacks diagnostic value for LARS, while a score of 21-29 indicates mild LARS and a score above 29 indicates major LARS.

    From 1 month postoperatively to 12 months postoperatively

  • FIQL

    The FIQL is a specific quality-of-life assessment scale applicable to the symptoms of colorectal cancer patients. It comprises 29 items, which are divided into four dimensions: lifestyle (10 items), coping/behavior restriction(9 items), depression/self-perception (7 items), and embarrassment (3 items).

    From 1 month postoperatively to 12 months postoperatively

  • Vaizey score

    The Wexner scale has five parts with a total score of 20, while the Vaizey scale is further refined on the basis of Wexner and has seven parts with a total score of 24. Higher scores on these scales indicate poorer anal functioning.

    From 1 month postoperatively to 12 months postoperatively

  • Wexner score

    The Wexner scale has five parts with a total score of 20, while the Vaizey scale is further refined on the basis of Wexner and has seven parts with a total score of 24. Higher scores on these scales indicate poorer anal functioning.

    From 1 month postoperatively to 12 months postoperatively

Secondary Outcomes (1)

  • Surgical complications

    From 1 month postoperatively to 12 months postoperatively

Study Arms (2)

J-pouch anastomosis group

Patient with ultra-low rectal cancer undergoing Sphincter- preserving surgery with one-stage anastomosis using a colon J-pouch.

Procedure: J-pouch anastomosis

direct anastomosis group

Patient with ultra-low rectal cancer undergoing Sphincter- preserving surgery with one-stage direct anastomosis.

Procedure: direct anastomosis

Interventions

Patient with ultra-low rectal cancer undergoing Sphincter- preserving surgery with one-stage anastomosis using a colon J-pouch.

J-pouch anastomosis group

Patient with ultra-low rectal cancer undergoing Sphincter- preserving surgery with one-stage direct anastomosis.

direct anastomosis group

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Our study population is the patients who diagnosed as ultra-low rectal adenocarcinoma cases by preoperative pathology and meet the eligibility criteria.

You may qualify if:

  • A confirmed diagnosis of intestinal cancer, with the lower edge of the tumour \<5 cm from the anus or \<3 cm from the dentate line, and treated with anus-preserving surgery;
  • No distant metastasis;
  • Age \>18 years old;
  • Voluntary enrollment in the study and signing of an informed consent.

You may not qualify if:

  • A combination of severe cardiopulmonary, hepatic, renal, and other underlying diseases with a greater anaesthetic risk (ASA ≥ grade 4);
  • preoperative anal stenosis and anal nonfunction;
  • temporary stoma diversion.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Shanghai Tenth People's Hospital, Yanchang Road, Jing'an District, Shanghai, China

Shanghai, Jingan, 200040, China

Location

MeSH Terms

Conditions

Rectal NeoplasmsEncopresisLow Anterior Resection SyndromeAnastomotic Leak

Condition Hierarchy (Ancestors)

Colorectal NeoplasmsIntestinal NeoplasmsGastrointestinal NeoplasmsDigestive System NeoplasmsNeoplasms by SiteNeoplasmsDigestive System DiseasesGastrointestinal DiseasesIntestinal DiseasesRectal DiseasesSigns and Symptoms, DigestiveSigns and SymptomsPathological Conditions, Signs and SymptomsBehavioral SymptomsBehaviorElimination DisordersMental DisordersColonic DiseasesPostoperative ComplicationsPathologic Processes

Study Officials

  • Cheng-Le Zhuang, MD, PhD

    Shanghai Tenth People's Hospital

    STUDY CHAIR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
1 Year
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

September 15, 2024

First Posted

September 19, 2024

Study Start

December 1, 2022

Primary Completion

March 11, 2025

Study Completion

April 11, 2025

Last Updated

September 19, 2024

Record last verified: 2024-09

Locations